XML 109 R77.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative and Other Relationships - Equity Method Investments (Details)
$ in Millions, ₩ in Billions
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
Nov. 30, 2018
USD ($)
Nov. 30, 2018
KRW (₩)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
KRW (₩)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
KRW (₩)
Jan. 31, 2020
USD ($)
Nov. 07, 2018
USD ($)
Schedule of Equity Method Investments [Line Items]                            
Loss on equity method investment               $ (16.1) $ 1.6          
Income tax (benefit) expense       $ (409.1) $ 446.1     (364.9) 738.2          
Collaboration profit sharing       (15.2) 21.8     53.3 93.5          
Total revenue       2,775.0 3,681.6     5,469.0 7,215.9          
ADUHELM                            
Schedule of Equity Method Investments [Line Items]                            
Total revenue       $ 1.6 $ 0.0     $ 1.6 $ 0.0          
Samsung Bioepis                            
Schedule of Equity Method Investments [Line Items]                            
Percentage of stake in entity         5.00%       5.00%          
Percentage of stake in entity maximum 49.90%     49.90%       49.90%   49.90%        
Payments to acquire additional investment in equity method investment   $ 676.6 ₩ 759.5       $ 676.6              
Amortization of basis differences                           $ 675.0
Loss recorded on Samsung Bioepis joint venture       $ 34.3 $ 15.1     $ 16.1 $ 0.4          
Investment in Samsung Bioepis $ 612.8     612.8       612.8   ₩ 691.6 $ 620.2 ₩ 673.8    
Income tax (benefit) expense       31.2       $ 31.2            
Biogen share of co-promotion profits or losses               50.00%            
Collaboration profit sharing       69.9 55.4     $ 138.4 127.2          
Eisai                            
Schedule of Equity Method Investments [Line Items]                            
Loss on research and development contracts terminated with Eisai           $ 45.0                
Loss on equity method investment       (40.1) (33.8)                  
Additional milestone payment         75.0                  
Eisai | ADUHELM                            
Schedule of Equity Method Investments [Line Items]                            
Loss on equity method investment       (45.0)       (45.0)            
Additional milestone payment 100.0     100.0 $ 75.0     100.0 $ 75.0          
Samsung Bioepis                            
Schedule of Equity Method Investments [Line Items]                            
Upfront and milestone payments made to collaborative partner           100.0                
Research and development expense           63.0                
Prepaid research and development expenses                         $ 37.0  
Estimated additional payments upon achievement of development and commercial milestones               195.0            
Additional milestone payment       15.0                    
Contract Option Exercise Fee           $ 60.0                
Due to Related Parties $ 158.7     $ 158.7       $ 158.7     $ 99.0      
Inventory | Samsung Bioepis                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment basis difference amortization period               1 year 6 months            
Developed technology | Samsung Bioepis                            
Schedule of Equity Method Investments [Line Items]                            
Equity method investment basis difference amortization period               15 years